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Over the past two decades, a steeply growing number of persons with chronic 
 non-cancer pain have been using opioid analgesics chronically to treat it, accompanied 
by a markedly increased prevalence of individuals with opioid-related misuse, opioid use 
disorders, emergency department visits, hospitalizations, admissions to drug treatment 
programs, and drug overdose deaths. This opioid misuse and overdose epidemic calls 
for well-designed randomized-controlled clinical trials into more skillful and appropriate 
pain management and for developing effective analgesics that have lower abuse lia-
bility and are protective against stress induced by chronic non-cancer pain. However, 
incomplete knowledge regarding effective approaches to treat various types of pain has 
been worsened by an under-appreciation of overlapping neurobiological mechanisms 
of stress, stress-induced relapse to opioid use, and chronic non-cancer pain in patients 
presenting for care for these conditions. This insufficient knowledge base has unfortu-
nately encouraged common prescription of conveniently available opioid pain-relieving 
drugs with abuse liability, as opposed to treating underlying problems using team-based 
multidisciplinary, patient-centered, collaborative-care approaches for addressing pain 
and co-occurring stress and risk for opioid use disorder. This paper reviews recent 
neurobiological findings regarding overlapping mechanisms of stress-induced relapse to 
opioid misuse and chronic non-cancer pain, and then discusses these in the context of 
key outstanding evidence gaps and clinical-treatment research directions that may be 
pursued to fill these gaps. Such research directions, if conducted through well-designed 
randomized-controlled trials, may substantively inform clinical practice in general medical 
settings on how to effectively care for patients presenting with pain-related distress and 
these common co-occurring conditions.
Keywords: chronic pain, addiction, opiate addiction, addiction treatment, opiate dependence, opioid dependence, 
substance use disorders, substance use disorder
inTRODUCTiOn
Recent evidence synthesis highlights substantial brain-mechanism overlaps between opioid use 
disorder and psychological-distress components of chronic non-cancer pain (1, 2). Medications 
that block reinstatement of opioid-seeking behavior in animal models may be useful for opioid 
use disorder treatment, and as will be discussed later, basic research suggests that some may 
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also have benefits for treating pain. This mini-review will 
present a synthesis of recent science regarding overlapping 
mechanisms of stress-induced relapse to opioid use that may 
also mediate the emotional stress-inducing components of 
chronic non-cancer pain. It will then discuss clinical-treatment 
research implications relevant to care management of patients 
with co-occurring opioid misuse and chronic non-cancer pain, 
evidence gaps, and treatment research directions that may be 
advanced to fill these gaps.
ReCenT TRAnSLATiOnAL ReSeARCH 
ReGARDinG STReSS-MODULATinG 
MeCHAniSM GOveRninG  
OPiOiD-SeeKinG BeHAviORS
Chronic opioid use and chronic non-cancer pain may render 
the brain extended amygdala system hypersensitive to the 
negative emotional lows, such as dysphoria, anxiety, irritabil-
ity, and hyperalgesia occurring following extended opioid use 
and during withdrawal (1), a psychological-distress state that 
heightens vulnerability to opioid-use relapse. In a reinstatement 
model of drug relapse, alpha-2 adrenergic receptor agonists (for 
example, clonidine or lofexidine) that inhibit noradrenaline/
norepinephrine activity in the extended amygdala block stress-
induced relapse to opioid and cocaine seeking (3, 4). Clonidine, 
an alpha-2 receptor agonist, has been used off-label for years in 
an opioid-using population to ameliorate symptoms of opioid 
withdrawal. Kowalczyk et  al. tested clonidine for relapse pre-
vention in opioid-dependence in the context of opioid agonist 
maintenance with buprenorphine (5). Perhaps alpha-2 receptor 
agonists combined with opioid agonist maintenance (such as 
buprenorphine) may be more effective than buprenorphine 
alone in extending abstinence from opioid use, related to a 
protective effect against stress-triggered opioid use. In a ran-
domized double-blind placebo-controlled trial enrolling 118 
treatment seekers with opioid use disorder, clonidine was tested 
for relapse prevention. Opioid treatment seekers who were 
maintained on buprenorphine maintenance and having attained 
initial abstinence – submitting opioid-free urines during weeks 
5 and 6 of treatment – were randomized to either continue on 
buprenorphine (and placebo) (n  =  57) or receive clonidine 
(0.1–0.3  mg per day) added to buprenorphine (n  =  61). In 
addition, to assess real-life stress and craving, these participants 
received handheld computers. These prompted reporting on 
past-hour stress or opioid craving four times a day at randomly 
prompted times during participant’s waking hours. Participants 
receiving buprenorphine plus clonidine exhibited a significantly 
longer time to lapse, compared with participants receiving 
buprenorphine plus placebo. The definition of lapse was any 
opioid-positive or missed urine test. Participants receiving 
buprenorphine plus clonidine also exhibited a longer duration 
of continuous opioid abstinence compared with participants 
receiving buprenorphine plus placebo (34.8 versus 25.5  days, 
Cohen’s d = 0.38). Clonidine was well tolerated as an adjunct 
to buprenorphine. The only specific symptom more likely to be 
reported in the clonidine group was dry mouth (5).
Thus, a clonidine adjunct, in conjunction with buprenorphine 
maintenance, seems to be an effective intervention that increases 
duration of abstinence in this population. Interestingly, real-time 
ambulatory data collected through ecological momentary assess-
ment suggested that clonidine worked in humans by partially 
decoupling daily-life stress from opioid craving. This was not 
the case in the buprenorphine plus placebo condition. Therefore, 
these findings are translational, relative to preclinical data (3): 
a medication (clonidine) identified in a preclinical model may 
effectively work-off label as a maintenance medication and adjunct 
to buprenorphine to enhance prevention of lapses to opioid use 
and prolong abstinence. In this study, the doses of clonidine used 
appeared to be safe and well tolerated in this population. For 
clinicians and patients, these findings are noteworthy in that they 
show how ecological momentary assessment results may be used 
to identify circumstances under which clonidine maintenance 
is most likely to be beneficial as an adjunct to buprenorphine 
maintenance: protecting against relapse-inducing properties of 
daily-life stress.
OveRLAPPinG BRAin CiRCUiTRY 
MeDiATinG PSYCHOLOGiCAL-STReSS 
COMPOnenT OF PAin AnD  
STReSS-inDUCeD OPiOiD USe
Neurobiological processes underlying stress-induced worsen-
ing of opioid use disorder following heavy opioid use and dur-
ing drug withdrawal share phenomenological similarities with 
aversive emotional aspects of chronic non-cancer pain (1, 2). 
Overlapping anti-reward anxiety-inducing neuroadaptations 
in the extended amygdala’s neural network [e.g., amplifying 
pathophysiological noradrenaline signaling, and interconnected 
corticotrophin-releasing factor/hormone (CRF/CRH) and 
dynorphin-mediated signaling] after repeated pain or opioid 
use and during opioid withdrawal may drive common mala-
daptive negative emotional responses to stress. The extended 
amygdala consists of interconnected structures, including the 
central nucleus of the amygdala, bed nucleus of the stria ter-
minalis, and nucleus accumbens shell. Indeed, these structures 
contain some of the highest levels of stress neurotransmitters 
and hormones, such as norepinephrine/noradrenaline and 
CRF/CRH. As with hyperactive CRF/CRH and norepinephrine 
tone, excessive dynorphins and kappa-opioid receptor activa-
tion in this neural network also heighten emotional-distress 
responses during withdrawal from opioid use and during 
chronic non-cancer pain. Affective hypersensitivity to stress by 
an overactive extended amygdala circuitry that creates aversive 
emotional states may motivate persons suffering from chronic 
non-cancer pain or opioid withdrawal to actively seek and take 
opioids to alleviate their negative emotions and psychological 
perceptions of pain. The extended amygdala sends efferent con-
nections to diencephalic and mesencephalic parts of the brain 
critically involved in emotional and motivational expression, 
including the lateral hypothalamus and the ventral tegmental 
area. Importantly, the anti-reward allostatic neuroadaptations 
described above may impact pain’s cross-sensitization with 
3Ghitza Overlapping Mechanisms: Pain and Opioid-Addiction
Frontiers in Psychiatry | www.frontiersin.org May 2016 | Volume 7 | Article 80
stress and stress-induced pathophysiology of reward circuitry 
maintaining addictive behaviors, following chronic opioid 
use. Hyperactivity of the brain stress circuits in the extended 
amygdala during such cross-sensitization has also been linked 
to accompanying decreased mesolimbic dopamine reward 
system activity  –  a loss of incentive-motivational function in 
the nucleus accumbens and interconnected prefrontal cortical 
circuitry that may also drive the negative emotional state of 
withdrawal that increases likelihood of relapse to opioid use and 
perception of pain (1, 6–10).
The similar nature of anti-reward pathophysiology in the 
extended amygdala increasing susceptibility to stress-related 
relapse to opioid use and recurrence of chronic non-cancer pain 
has important clinical therapeutic implications. It calls for system-
atic lines of research into how to effectively develop an integrative 
patient-centered care approach for addressing the United States 
public health epidemic of rising morbidity and mortality related 
to misuse of opioids (i.e., using multidisciplinary, collaborative 
care to safely and effectively manage psychological stress and pain 
together with common comorbid conditions, such as opioid use 
disorders).
RATiOnALe AnD innOvATive ReSeARCH 
QUeSTiOnS ReGARDinG  
PATienT-CenTeReD CARe APPROACH 
ADDReSSinG STReSS-ReDUCTiOn 
TOGeTHeR wiTH TReATinG CHROniC 
nOn-CAnCeR PAin
Over the past two decades, a steeply growing number of persons 
with chronic non-cancer pain have been using opioid analgesics 
chronically to treat it. A subset of the millions of individuals 
who have chronic or persistent pain use opioids (particularly 
full mu-opioid receptor agonists) to treat it (11, 12). The number 
of opioid analgesic prescriptions has increased fourfold in the 
United States over the past two decades, which is concerning 
in light of the accompanying markedly increased prevalence 
of individuals with opioid-related misuse, opioid use disor-
ders, opioid-related emergency department visits, admission 
to drug treatment programs, overdose deaths, and hepatitis 
C  virus prevalence (11–22). This United States opioid misuse 
and overdose epidemic calls for well-designed prospective 
randomized-controlled trial research into more skillful and 
appropriate pain management and for developing effective anal-
gesics that have lower abuse liability and are protective against 
stress induced by chronic non-cancer pain. This is particularly 
important in light of high prevalence of chronic pain patients 
who also suffer from co-occurring anxiety or mood disorders. 
Thus, research-informed strategies are sorely needed to prevent 
opioid overdoses and decrease opioid misuse, particularly in 
high-risk populations for opioid use disorders, such as patients 
using opioids for chronic non-cancer pain who are susceptible 
to stress (11, 12).
One potential solution is to advance well-designed 
randomized-controlled trials on analgesic comparative 
effectiveness of combined partial mu-opioid receptor agonists 
(i.e.,  buprenorphine, which has less abuse liability than full 
mu-opioid receptor agonists) and alpha-2 adrenergic receptor 
agonists [which have been shown to have analgesic efficacy in 
their own right but less abuse liability relative to full mu-opioid 
receptor agonists (23–30)], compared to full mu-opioid receptor 
agonists for treating chronic non-cancer pain. As discussed, 
alpha-2 adrenergic receptor agonists may confer added benefits, 
above and beyond mu-opioid receptor partial agonists, of pro-
tecting against stress-induced opioid misuse. For instance, an 
interesting research question upon which to design a comparative 
effectiveness research trial would be the following: among adults 
at risk for an opioid use disorder who are already using mu-opioid 
agonists to treat chronic non-cancer pain, what are comparative 
benefits versus harms of continuing such opioids versus switch-
ing to partial mu-opioid receptor agonist buprenorphine, either 
(a) alone or (b) combined with an alpha-2 adrenergic receptor 
agonist (e.g., clonidine, lofexidine, or guanfacine)? What is the 
longer-term durability (>1  year) of these outcomes related to 
pain, function, life satisfaction, recovery from opioid use, and 
quality of life? The rationale for the latter comparator would be 
neurobiological research, suggesting that analgesic benefit of a 
combination mechanism-of-action approach to treating pain. 
Relatively, low doses of mu-opioid receptor agonists combined 
with alpha-2 adrenergic receptor agonists may have synergistic 
pain-relieving benefits, with a better safety profile than higher 
doses of mu-opioid receptor agonists (31–38). For such research 
questions to be informative to clinicians, it would also be help-
ful to test the comparative effectiveness of different regimens 
for initiating and titrating these agents for providing maximal 
functional, stress-reducing, and analgesic benefits and for mini-
mizing harm.
Cannabidiol (CBD) is another promising therapeutic target 
that merits systematic, rigorous clinical research on its effec-
tiveness in treating stress-induced relapse to opioid misuse 
and neuropathic chronic non-cancer pain. CBD is a bioactive 
cannabinoid found in marijuana (Cannabis sativa) with low 
reinforcing properties and anxiolytic-like effects (39–42). 
Research in a rodent relapse model suggests that repeated CBD 
administration (5–20  mg/kg) inhibits cue-induced reinstate-
ment of heroin-seeking behavior. Notably, these effects persisted 
2  weeks following its administration, a reduction desirable 
for heroin relapse prevention (42). No adverse side-effects 
were noted to account for this finding (42). In addition to its 
anxiolytic effects, CBD may also reduce the reward-facilitating 
effect of morphine (43). CBD exerts anxiolytic effects partially 
through serotonin 5-HT-1A receptor activation in the dorsal 
periaqueductal gray (41). Blockade of 5-HT-1A receptors by 
a 5-HT-1A receptor antagonist reversed CBD’s inhibition of 
morphine’s reward-facilitating effects, suggesting that 5-HT-
1A receptors may play a role not only in CBD’s anxiolytic 
properties but also in its opioid reward-inhibiting effects (43). 
These preclinical findings suggest that CBD, perhaps acting 
through 5-HT-1A receptor activation to reduce anxiety-related 
opioid use, may be a promising therapeutic target for opioid 
use disorder. Pilot data from a human laboratory study in 
recently heroin-abstinent volunteers with opioid use disorder 
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extended these findings. In these non-treatment seekers, a 
single  administration of oral CBD (400 or 800  mg) blunted 
cue-induced heroin craving induced by a heroin video cue, 
compared with placebo. This single administration of CBD 
maintained a reduction in heroin craving when assessed 24 h 
later. One hour following a single administration of CBD, CBD 
also attenuated cue-induced anxiety induced by a heroin cue, 
compared with placebo (44).
Importantly, a double-blind placebo-controlled cross-over 
study of CBD, co-administered with an intravenous strong 
mu-opioid receptor agonist fentanyl, showed that oral CBD 
(400 or 800 mg) was safe and well tolerated with no significant 
pharmacokinetic changes with opioid co-administration (45). 
To extend these preliminary safety and efficacy results, rigor-
ous clinical-trial research is needed with treatment-seeking 
outpatients having opioid use disorder. For example, it would 
be helpful to conduct a dose–response study in a double-blind, 
randomized placebo-controlled trial where recently heroin-
abstinent treatment-seeking outpatients would receive a course 
of one of several doses of CBD or placebo to test CBD’s effec-
tiveness as an opioid relapse-prevention agent. As mentioned, 
CBD’s inhibition of opiate-mediated reward through activation 
of serotonin 5-HT-1A receptors may be germane to its effects 
on blocking opioid reinforcement and reducing anxiety-related 
susceptibility to opioid use. This hypothesized 5-HT-1A 
mechanism-of-action merits further systematic and rigorous 
translational research.
In addition to its anxiolytic effects, preclinical research 
also suggests that CBD may also have pain-relieving effects 
in reducing neuropathic pain, partially due to facilitating α3 
glycine and serotonin 5-HT-1A receptor activation (46–48), 
which merits systematic clinical research into this mechanism 
of action. Furthermore, in placebo-controlled randomized tri-
als, an oromucosal spray formulation [nabiximols, trade name 
Sativex® approved in the United Kingdom (UK) for treatment 
of spasticity due to multiple sclerosis] containing about a 1:1 
mixture of purified CBD and tetrahydrocannabinol (THC) 
constituents was found to be efficacious in reducing neuro-
pathic pain (49–51). Phase-III double-blind placebo-controlled 
randomized trials in United States populations are needed to 
test the effectiveness of this promising compound for these 
indications. In addition, an interesting clinically meaningful 
research question worth studying in a well-designed compara-
tive effectiveness research trial may be the following. Among 
individuals who have shown signs of misuse while using long-
term prescription opioids for neuropathic pain, what are the 
comparative benefits and harms of continuing conventional 
opioids (with non-pharmacological co-interventions) versus 
switching to nabiximols (with or without non-pharmacologic 
co-interventions)? What is the longer-term durability (>1 year) 
of these outcomes related to pain, function, and quality of life? 
Taken together, the above findings suggest multiple potential 
applications of the cannabinoid CBD in treatment of opioid 
misuse as well as some forms of chronic non-cancer pain, which 
merits randomized-controlled trials to test effectiveness, such 
as the examples discussed above.
neeD FOR PReCiSiOn MeDiCine 
APPROACHeS TO TReATinG CHROniC 
nOn-CAnCeR PAin, STReSS, AnD 
CHROniC COMORBiD COnDiTiOnS
A key question regarding the putative therapeutic targets and 
approaches mentioned above would be: for which patient sub-
groups are the various options most beneficial to maximize thera-
peutic benefit while minimizing risks for harm, in the broader 
context of multidisciplinary pain management which may 
involve psychosocial, shared decision-making co-intervention? 
Chronic non-cancer pain is a complex neuropsychological syn-
drome which may have multifaceted biological and psychosocial 
mediators that may qualitatively differ between distinct patient 
subgroups (52, 53). Thus, to be useful to clinical practice, addi-
tional precision medicine research should be conducted in gen-
eral medical settings to assess which chronic pain types, related 
diseases (such as opioid use disorder), and patients are most 
likely to clinically benefit from such therapeutic options, versus 
from opioids typically prescribed to treat chronic non-cancer 
pain. This type of research may also test how to effectively tailor 
multidisciplinary pain management to individualized pain pro-
files, patient preferences, risks, and biopsychosocial needs – and 
tailored to the myriad etiologies and presentations of pain and 
those of other common co-occurring conditions, such as opioid 
use disorder. In addition, it would be useful to conduct such 
comparative effectiveness research in a manner by which patients’ 
perspectives would be addressed using a shared decision-making 
approach to evaluate how to improve overall well-being and daily 
psychosocial functioning from clients’ standpoint and desired 
outcomes, while simultaneously reducing both psychological 
distress and physical dimensions of pain (54).
This research area could, thus, also test a range of evidence-
based, patient-centered strategies for managing chronic non-
cancer pain. Complementary precision medicine research would 
also be helpful to identify psychiatric, genetic, physiological, 
sociodemographic, cultural, and other predictors of responsive 
versus non-responsive patients, incorporating well-accepted and 
established operational definitions of chronic non-cancer pain 
(11, 54). Furthermore, rigorous pragmatic research needs to be 
advanced regarding how to effectively implement a multimodal, 
team-based collaborative-care approach to chronic pain manage-
ment in general medical settings, which may involve a multidis-
ciplinary collaboration of physician aids as needed (for example, 
nurses, psychologists, social workers, pharmacists, etc.) based on 
comprehensive clinical assessment and biopsychological model 
of care, working in close coordination to enhance quality and 
continuity of evidence-based holistic care (54). Such an approach 
calling for integrated, interdisciplinary team-based pain manage-
ment is consistent with a need to treat the whole person through 
a patient-centered care approach, within the context of the 
entire medical history – including chronic co-occurring condi-
tions – and consistent with personalized needs and preferences, 
not just the pain condition. This care management approach 
is also reflective of chronic non-cancer pain not being a single 
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entity or syndrome but being a multidimensional problem and 
recognizing a need to systematically address in treatment plans 
the patients’ comorbid conditions, goals of care, recovery and 
overall well-being, and concomitant medications. Importantly, 
precision medicine research should include validated clinically 
meaningful research assessments for identifying patient-reported 
outcomes on risks and benefits from chronic opioid use, which 
may be customized to different patient subgroups in general 
medical settings (11, 54). It would be helpful to assess the degree 
to which such research assessments accurately predict the risks of 
opioid misuse, addiction, or overdose. Findings from prospective 
randomized-controlled trials in the aforementioned priority areas 
could be supplemented by informative longitudinal data from 
large pain patient registries linked to electronic health record 
systems (EHRs), in order to accelerate hypothesis generation and 
refinement to generate timely knowledge within a rapid-learning 
healthcare system (54).
In conclusion, considerable neurobiological overlaps exist in 
neuroadaptations mediating negative psychological components 
of pain and motivational impact of stress in maintaining or 
reinstating opioid addictive behaviors. These similarities call for 
a systematic precision-medicine research agenda, such as the 
one described above, on how to effectively tailor management of 
co-occurring chronic non-cancer pain and opioid use disorders 
in a patient-centered manner using a shared decision-making, 
multidisciplinary approach. For this approach to address a per-
son’s holistic needs during recovery, care management may take 
account of patients’ complete medical history, including anxiety, 
mood, and other psychiatric comorbidities, readiness to change 
health-risk behaviors and reasons or hesitancy for doing so, 
and incorporating these factors into treatment plans to support 
 self-management behaviors toward recovery. Pragmatic research 
may also be conducted to examine how to address patients’ 
perceived barriers for recovery, as well as individualized values 
and preferences for treatment options, toward facilitating health 
promotion behaviors for improving overall functioning and well-
being. Such precision medicine type research could bear fruit in 
establishing which patient populations benefit most from different 
pain- and substance-use care management regimens. Thereby, this 
pragmatic clinical research may pave the way to develop evidence-
based, actionable clinical decision support tools embedded in 
EHRs for person-centered approaches to chronic pain manage-
ment (and common co-occurring conditions), and proactive risk 
identification and mitigation strategies, in clinical practice.
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